Illustrative photo from Reuters |
"Scaling up the raw material supply chain took longer than expected", the spokesperson said.
Pfizer’s vaccine relies on a two-dose regimen, meaning 50 million doses is enough to inoculate 25 million people. Challenges in the supply chain for the raw materials used in its vaccine and later-than-expected results from clinical trial play a role in the decision, Pfizer said.